Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

(2017) Megan Lo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Silencing strategies for therapy of SOD1-mediated ALS

(2017) Brigitte van Zundert et al.   NEUROSCIENCE LETTERS

Amyotrophic Lateral Sclerosis

(2017) Robert H. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synaptic pathology: A shared mechanism in neurological disease

(2016) Christopher M. Henstridge et al.   AGEING RESEARCH REVIEWS

Diverging roles for Lrp4 and Wnt signaling in neuromuscular synapse development during evolution

(2016) Leonor Remédio et al.   GENES & DEVELOPMENT

Neuromuscular junctions are pathological but not denervated in two mouse models of spinal bulbar muscular atrophy

(2016) Jessica E. Poort et al.   HUMAN MOLECULAR GENETICS

Decoding ALS: from genes to mechanism

(2016) J. Paul Taylor et al.   NATURE

Myasthenia gravis: subgroup classification and therapeutic strategies

(2015) Nils Erik Gilhus et al.   LANCET NEUROLOGY

Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment

(2015) Andrew G Engel et al.   LANCET NEUROLOGY

RNA-targeted Therapeutics for ALS

(2015) Linga V. Reddy et al.   Neurotherapeutics

Functional and Morphological Assessment of Diaphragm Innervation by Phrenic Motor Neurons

(2015) Melanie Martin et al.   Jove-Journal of Visualized Experiments

DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction

(2014) S. Arimura et al.   SCIENCE

Inhibiting drug efflux transporters improves efficacy of ALS therapeutics

(2014) Michael R. Jablonski et al.   Annals of Clinical and Translational Neurology

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

(2013) Timothy M Miller et al.   LANCET NEUROLOGY

Early Changes of Neuromuscular Transmission in the SOD1(G93A) Mice Model of ALS Start Long before Motor Symptoms Onset

(2013) Mariana C. Rocha et al.   PLoS One

MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters

(2013) Inga Koneczny et al.   PLoS One

MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4

(2013) M. G. Huijbers et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Role of MuSK in Synapse Formation and Neuromuscular Disease

(2013) S. J. Burden et al.   Cold Spring Harbor Perspectives in Biology

Characterization of early pathogenesis in the SOD1G93Amouse model of ALS: part I, background and methods

(2013) Sharon Vinsant et al.   Brain and Behavior

Characterization of early pathogenesis in the SOD1G93Amouse model of ALS: part II, results and discussion

(2013) Sharon Vinsant et al.   Brain and Behavior

Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses

(2012) Norihiro Yumoto et al.   NATURE

Shared Resistance to Aging and ALS in Neuromuscular Junctions of Specific Muscles

(2012) Gregorio Valdez et al.   PLoS One

Increasing MuSK Activity Delays Denervation and Improves Motor Function in ALS Mice

(2012) María J. Pérez-García et al.   Cell Reports

Agrin Binds to the N-terminal Region of Lrp4 Protein and Stimulates Association between Lrp4 and the First Immunoglobulin-like Domain in Muscle-specific Kinase (MuSK)

(2011) Wei Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the SOD1G93A Mouse Model of ALS

(2011) Angelo C. Lepore et al.   PLoS One

Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L

(2010) P. T. Hallock et al.   GENES & DEVELOPMENT

Lrp4 Is a Receptor for Agrin and Forms a Complex with MuSK

(2008) Natalie Kim et al.   CELL

LRP4 Serves as a Coreceptor of Agrin

(2008) Bin Zhang et al.   NEURON